LOE and behold, massive BMS merger near with Astrazeneca? “Highly complementary” pipelines could mean a merger deal would benefit Astrazeneca plc as well as Bristol Myers Squibb Co. (BMS), Leerink analyst David Risinger said in a report. The potential setup had Wall Street abuzz as published rumors made the rounds. Both firms were keeping mum.